Bernard Mallee: At the European Parliament in Brussels today, Anne Kerber joined a panel, organized by the TRANSFORM Alliance, that explored the future policy ecosystem for advanced therapy medicinal products in the EU.

Bernard Mallee, Director of International Policy Communications at Bristol Myers Squibb, shared on LinkedIn:

“At the European Parliament in Brussels today, Anne Kerber, SVP and Head of Cell Therapy Development at Bristol Myers Squibb joined a panel, organized by the TRANSFORM Alliance, that explored the future policy ecosystem for advanced therapy medicinal products in the EU.

As EU policymakers consider new laws affecting innovation in medicines through the revised General Pharma Legislation, we are reminded that a future-proofed regulatory framework is the way to stretch our science for better patient care.

Cell therapy is a revolution in medicine and cancer immunotherapy. It paves the way for a promising shift in the future paradigm of cancer care. But cell therapy is uniquely complex and it faces significant challenges, including the development process, scaling manufacturing, adapting supply chains, and updating and aligning regulatory pathways.

These challenges can be tackled through open and constructive dialogue, leading to new ways of working between regulators, payers, industry and others. The TRANSFORM Alliance is a successful example of evidence-based cross-stakeholder dialogue.

More collaborations like this one are needed so that more European patients can realize the benefits of innovation. Thanks to Billy Kelleher MEP for his thoughtful remarks at the event and for meeting Anne.”

Source: Bernard Mallee/Linkedin